Parabolic Drugs Ltd. announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, the standalone company reported net sales of INR 242.6 million against INR 201.3 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 121.2 million against INR 1,516.0 million a year ago. Loss from ordinary activities before tax was INR 446.3 million against INR 1,786.4 million a year ago. Net loss was INR 454 million against INR 1,786.4 million a year ago. Basic and diluted loss per share before and after extraordinary items was INR 7.33 against INR 28.86 a year ago. For the nine months, the standalone company reported net sales of INR 492.4 million against INR 609.9 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 707.9 million against INR 2,780.6 million a year ago. Loss from ordinary activities before tax was INR 1,635.1 million against INR 3,573.5 million a year ago. Net loss was INR 1,658.3 million against INR 3,573.5 million a year ago. Basic and diluted loss per share before and after extraordinary items was INR 26.79 against INR 57.74 a year ago.